Sept. 17, 2024

Three applications for New Technology Ambulatory Payment Classifications (APC) for medical 3D printing services were recently submitted by American College of Radiology® (ACR®) Economics Coding & Nomenclature Committee member Frank Rybicki, MD, PhD, FACR in coordination with ACR Economics staff.

Under the Hospital Outpatient Prospective Payment System (HOPPS), new and emerging technologies can apply for reimbursement under a New Technology APC until the Centers for Medicare and Medicaid Services (CMS) is able to collect enough claims data, generally 2 to 3 years, when it can then be placed into an appropriate clinical APC.

The applications were submitted with supporting documentation for three distinct levels of medical 3D printing: basic, intermediate, and complex. Medical 3D printing services are performed for various clinical indications and utilize substantial hospital resources which warrants separate payment. CMS will review the submissions to determine whether they meet the criteria to receive reimbursement under the HOPPS for 2025.

For more information, contact Kimberly Greck, ACR Senior Economic Policy Analyst.


Related ACR News

  • Make America Healthy Again

    President Trump released an Executive Order (EO) establishing the "Make America Healthy Again (MAHA) Commission,” Feb. 13 to be led by the new Department of Health and Human Services Secretary Robert F. Kennedy Jr.

    Read more
  • Scope of Practice Bills Introduced At State Legislative Level

    The American College of Radiology® (ACR®) is tracking more than 58 scope of practice bills across 22 states with more expected to be considered.

    Read more
  • ACR Others Challenge MAC Position on Minimally Invasive Arthrodesis of the Sacroiliac Joint

    The American College of Radiology® (ACR®) and other medical specialty societies that use or perform interventional pain and spine procedures told three of the seven Medicare Administrative Contractors (MACs) that implementation of a new policy as written could limit access to a safe, effective and durable treatment option, potentially exacerbating healthcare disparities among Medicare patients.

    Read more